Tiotropium HandiHaler^® and Respimat^® in COPD: a pooled safety analysis

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary diseaseGOLD updated 2014 Available from: http://www.goldcopd.com/uploads/users/files/GOLD_Report_2014_Oct30.pdfAccessed December 15, 2014
   Google Scholar
• BrusascoVHodderRMiravitllesMKorduckiLTowseLKestenSHealth outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDThorax20035839940412728159
   PubMed Web of Science ®Google Scholar
• CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J20021921722411866001
   PubMed Web of Science ®Google Scholar
• TashkinDPCooperCBThe role of long-acting bronchodilators in the management of stable COPDChest200412524925914718448
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med20083591543155418836213
   PubMed Web of Science ®Google Scholar
• VinckenWvan NoordJAGreefhorstAPDutch/Belgian Tiotropium Study GroupImproved health outcomes in patients with COPD during 1 yr’s treatment with tiotropiumEur Respir J20021920921611871363
   PubMed Web of Science ®Google Scholar
• DusserDBravoMLIaconoPThe effect of tiotropium on exacerbations and airflow in patients with COPDEur Respir J20062754755516507855
   PubMed Web of Science ®Google Scholar
• HalpinDMenjogeSVielKPatient-level pooled analysis of the effect of tiotropium on COPD exacerbations and related hospitalisationsPrim Care Respir J20091810611319407916
   PubMedGoogle Scholar
• NiewoehnerDERiceKCoteCPrevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trialAnn Intern Med200514331732616144890
   PubMed Web of Science ®Google Scholar
• Boehringer IngelheimSpiriva 18 microgram inhalation powder, hard capsule. Summary of Product Characteristics (SPC), Electonic Medicines Compendium (EMC) Available from: http://www.medicines.org.uk/emc/medicine/10039/SPC/Spiriva+18+microgram+inhalation+powder%2c+hard+capsule/Accessed July 19, 2013
   Google Scholar
• Boehringer IngelheimSpiriva Respimat 2.5 microgram solution for inhalation. Summary of Product Characteristics (SPC), Electonic Medicines Compendium (EMC) Available from: http://www.medicines.org.uk/emc/medicine/20134/SPCAccessed July 19, 2013
   Google Scholar
• BatemanEDTashkinDSiafakasNA one-year trial of tiotropium Respimat plus usual therapy in COPD patientsRespir Med20101041460147220620037
   PubMed Web of Science ®Google Scholar
• IchinoseMFujimotoTFukuchiYTiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patientsRespir Med201010422823619969446
   PubMed Web of Science ®Google Scholar
• van NoordJACornelissenPJAumannJLPlatzJMuellerAFogartyCThe efficacy of tiotropium administered via Respimat Soft Mist inhaler or HandiHaler in COPD patientsRespir Med2009103222919022642
   PubMed Web of Science ®Google Scholar
• HohlfeldJMSharmaAvan NoordJAPharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary diseaseJ Clin Pharmacol201454440541424165906
   PubMed Web of Science ®Google Scholar
• Boehringer IngelheimBoehringer Ingelheim submits application in Europe to extend the indication for the use of tiotropium Respimat^® to the treatment of asthma in adults aged 18 years and over [press release archive: asthma]Ingelheim, GermanyBoehringer Ingelheim20131113 Available from: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/13_november_2013_tiotropium.htmlAccessed December 15, 2014
   Google Scholar
• CelliBDecramerMKestenSLiuDMehraSTashkinDPUPLIFT Study InvestigatorsMortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200918094895519729663
   PubMed Web of Science ®Google Scholar
• Boehringer IngelheimTiotropium (Spiriva) Respimat: evaluation of fatal eventsIngelheim, GermanyBoehringer Ingelheim Available from: http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/Pooled%20analysis/PA_205.372_251_252_254_255_U10-3255-01.pdfAccessed January 30, 2014
   Google Scholar
• DongYHLinHHShauWYWuYCChangCHLaiMSComparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trialsThorax201368485623042705
   PubMed Web of Science ®Google Scholar
• KarnerCChongJPoolePTiotropium versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20127CD00928522786525
   PubMed Web of Science ®Google Scholar
• LokeYKSinghSRisks associated with tiotropium in chronic obstructive pulmonary disease: overview of the evidence to dateTher Adv Drug Safe20123123131
   Google Scholar
• SinghSLokeYKEnrightPLFurbergCDMortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trialsBMJ2011342d321521672999
   PubMed Web of Science ®Google Scholar
• BarrRGBourbeauJCamargoCARamFSTiotropium for stable chronic obstructive pulmonary disease: a meta-analysisThorax20066185486216844726
   PubMed Web of Science ®Google Scholar
• CelliBDecramerMLeimerIVogelUKestenSTashkinDPCardiovascular safety of tiotropium in patients with COPDChest2010137203019592475
   PubMed Web of Science ®Google Scholar
• KestenSJaraMWentworthCLanesSPooled clinical trial analysis of tiotropium safetyChest20061301695170317166984
   PubMed Web of Science ®Google Scholar
• KestenSCelliBDecramerMLeimerITashkinDTiotropium HandiHaler in the treatment of COPD: a safety reviewInt J Chron Obstruct Pulmon Dis2009439740920037679
   PubMedGoogle Scholar
• RodrigoGJCastro-RodriguezJANanniniLJPlaza MoralVSchiaviEATiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysisRespir Med20091031421142919556116
   PubMed Web of Science ®Google Scholar
• SalpeterSRDo inhaled anticholinergics increase or decrease the risk of major cardiovascular events?: a synthesis of the available evidenceDrugs2009692025203319791824
   PubMed Web of Science ®Google Scholar
• WiseRAAnzuetoACottonDTIOSPIR InvestigatorsTiotropium Respimat inhaler and the risk of death in COPDN Engl J Med20133691491150123992515
   PubMed Web of Science ®Google Scholar
• ICH harmonised tripartite guidelines. Clinical safety data management: definitions and standards for expidited reporting E2AInternational Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human UseOctober 271994
   Google Scholar
• TashkinDPMetzdorfNHallmanCKoenen-BergmannMKupasKDahlRSafety of tiotropium in renally impaired patientsEur Respir J201444Suppl 58 Abstract 923
   Google Scholar
• JenkinsCRMore than just reassurance on tiotropium safetyN Engl J Med2013369161555155624131181
   PubMed Web of Science ®Google Scholar
• LeeTAPickardASAuDHBartleBWeissKBRisk for death associated with medications for recently diagnosed chronic obstructive pulmonary diseaseAnn Intern Med200814938039018794557
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKFurbergCDInhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysisJAMA20083001439145018812535
   PubMed Web of Science ®Google Scholar
• VoshaarTLapidusRMaleki-YazdiRA randomized study of tiotropium Respimat Soft Mist inhaler vs ipratropium pMDI in COPDRespir Med2008102324117996436
   PubMed Web of Science ®Google Scholar
• BatemanESinghDSmithDEfficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studiesInt J Chron Obstruct Pulmon Dis2010519720820714373
   PubMedGoogle Scholar
• WedzichaJACalverleyPMSeemungalTAHaganGAnsariZStockleyRAINSPIRE InvestigatorsThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med2008177192617916806
   PubMed Web of Science ®Google Scholar
• KeatingGMTiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary diseaseDrugs20127227330022217233
   PubMed Web of Science ®Google Scholar
• ChurchABeeraheeMBrooksJMehtaRShahPDose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over studyBMC Pulm Med201414224393134
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med2013119920924429126
   PubMed Web of Science ®Google Scholar
• ShavelleRMPaculdoDRKushSJManninoDMStraussDJLife expectancy and years of life lost in chronic obstructive pulmonary disease: findings from the NHANES III follow-up studyInt J Chron Obstruct Pulmon Dis2009413714819436692
   PubMedGoogle Scholar
• ManninoDMDohertyDEBuistSAGlobal initiative on obstructive lung disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) studyRespir Med200610011512215893923
   PubMed Web of Science ®Google Scholar
• CalverleyPMLeeATowseLvan NoordJWitekTJKelsenSEffect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary diseaseThorax20035885586014514937
   PubMed Web of Science ®Google Scholar
• McNicholasWTCalverleyPMLeeAEdwardsJCLong-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPDEur Respir J20042382583115218993
   PubMed Web of Science ®Google Scholar
• DonohueJFvan NoordJABatemanEDA 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterolChest2002122475512114338
   PubMed Web of Science ®Google Scholar
• O’DonnellDEFlügeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEur Respir J20042383284015218994
   PubMed Web of Science ®Google Scholar
• VerkindreCBartFAguilaniuBThe effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary diseaseRespiration20067342042716484769
   PubMed Web of Science ®Google Scholar
• CelliBZuWallackRWangSKestenSImprovement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumesChest20031241743174814605043
   PubMed Web of Science ®Google Scholar
• MaltaisFHamiltonAMarciniukDImprovements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPDChest20051281168117816162703
   PubMed Web of Science ®Google Scholar
• CasaburiRKukafkaDCooperCBWitekTJJrKestenSImprovement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPDChest200512780981715764761
   PubMed Web of Science ®Google Scholar
• AmbrosinoNFoglioKBalzanoGPaggiaroPLLessiPKestenSTiotropium Multicentric Italian Study GroupTiotropium and exercise training in COPD patients: effects on dyspnea and exercise toleranceInt J Chron Obstruct Pulmon Dis2008377178019281092
   PubMedGoogle Scholar
• TonnelABPerezTGrosboisJMVerkindreCBravoMLBrunMTIPHON study groupEffect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPDInt J Chron Obstruct Pulmon Dis2008330131018686739
   PubMedGoogle Scholar
• BeehKMBeierJBuhlRStark-LorenzenPGerkenFMetzdorfNATEM-StudiegruppeEfficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severitiesPneumologie20066034134616761228
   PubMedGoogle Scholar
• ChanCKMaltaisFSigouinCHaddonJMFordGTSAFE Study GroupA randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary diseaseCan Respir J20071446547218060091
   PubMed Web of Science ®Google Scholar
• PowrieDJWilkinsonTMDonaldsonGCEffect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPDEur Respir J20073047247817504798
   PubMed Web of Science ®Google Scholar
• FreemanDLeeAPriceDEfficacy and safety of tiotropium in COPD patients in primary care–the SPiRiva Usual CarE (SPRUCE) studyRespir Res200784517605774
   PubMed Web of Science ®Google Scholar
• JohanssonGLindbergARombergKNordstromLGerkenFRoquetABronchodilator efficacy of tiotropium in patients with mild to moderate COPDPrim Care Respir J20081716917518536860
   PubMedGoogle Scholar
• MoitaJBarbaraCCardosoJTiotropium improves FEV1 in patients with COPD irrespective of smoking statusPulm Pharmacol Ther20082114615117693107
   PubMed Web of Science ®Google Scholar
• CovelliHBhattacharyaSCassinoCConoscentiCKestenSAbsence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary diseasePharmacotherapy2005251708171816305289
   PubMed Web of Science ®Google Scholar
• CrinerGJSharafkhanehAPlayerREfficacy of tiotropium inhalation powder in african-american patients with chronic obstructive pulmonary diseaseCOPD20085354118259973
   PubMedGoogle Scholar
• MagnussenHBugnasBvanNJSchmidtPGerkenFKestenSImprovements with tiotropium in COPD patients with concomitant asthmaRespir Med2008102505617920256
   PubMed Web of Science ®Google Scholar
• SciurbaFCSiafakasNTroostersTThe efficacy of safety of tiotropium HandiHaler^®, 18 ìg, once daily plys prn salbutamol versus placebo plus prn salbutamolin COPD subjects naïve to maintenance therapyAmerican Thoracic Society International Conference2011 May 13–18Denver, CO Abstract 21005
   Google Scholar
• CooperCBCelliBRJardimJRTreadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trialChest201314449049723558890
   PubMed Web of Science ®Google Scholar
• LittnerMRvanNJMoroni-ZentgrafPSigmundRJosephEKarpelJPhase IIB dose-finding study of BEA2180 via Respimat® in patients with chronic obstructive pulmonary disease (COPD)Respirology201217Suppl 244
   Google Scholar
• AbrahamsRMoroni-ZentgrafPRamsdellJSchmidtHJosephEKarpelJSafety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPDRespir Med201310785486223490224
   PubMed Web of Science ®Google Scholar